axolight

Export presentation Axolight 05/2012 | www.soliance.com

AXOLIGHT Innovative lightening active ingredient

• Ecocert approved • New mode of action in melanogenesis

Export presentation Axolight 05/2012 | www.soliance.com 2

• The pigmentation of the skin results from the presence of eumelanin (black-brown) and pheomelanin (yellow-orange) in the epidermis

• Melanin is synthesized, in 4 steps, in specialised cells, the melanocytes, which transfer them to the keratinocytes.

Bio

log

ica

l co

nte

xt

DE

RM

IS

E

PID

ER

MIS

Maturation stages of melanosomes

into the melanocytes.


AXOlight : ArabinoXylo-Oligosaccharides

Structure : Xylose chain substitued by Arabinose

Mean degree of Polymerization : 4

Str

uc

ture


Fabrication process is composed in 5 major steps :

Raw material destarching (without solvent)

Enzymatic hydrolyse of hemicelluloses (specific)

Separation of arabinoxylanes

Purification

Standardization of the concentration

Pro

du

ctio

n p

roc

ess


In Vitro test- Protocol Normal human melanocytes are incubated 72 hours at 37°C, on a humid atmosphere with 5% of CO2. Incubation is made with: - Culture medium only - with Kojic acid at 0,003% (positive reference) - or with increasing concentration of Axolight Melanin dosage is measured with a spectrophotometer at 405 nm.

Axolight inhibits melanogenesis more efficiently than kojic acid

Axo

ligh

t in

hib

its

the

me

lan

og

en

esi

s

Inhibition of melanogenesis

Axolight inhibits melanogenesis with a dose effect


In Vitro test - Protocole Tyrosinase activity is quantified with a spectrophotometer, with L-DOPA (substrate of tyrosinase). After the action of the tyrosinase, L-DOPA is transformed in dopachrom which is a colored compound detectable by spectrocolorimeter at 490 nm.

Axolight inhibits melanogenesis via tyrosinase and another pathway

Inh

ibitio

n o

f m

ela

no

ge

ne

sis:

ty

rosi

na

se a

ke

y e

nzy

me

Even though Axolight significantly inhibits melanogenesis, it is only partially due to its inhibition of tyrosinase indicating that it works in another metabolic pathway melanogenesis.

Inhibition of tyrosinase activity


Me

lan

og

en

esi

s: n

ew

da

ta

1. If tyrosine is at a low concentration, TRP1 can induce transformation of tyrosine in LDOPA.

2. The augmentation of LDOPA quantity induce the activation of tyrosinase.

3. TRP-1 forms a complex with activated tyrosinase to stabilize it and increase its activity.

References:

Human tyrosinase related protein-1 (TRP-1)

Tyrp1 and Oculocutaneous Albinism Type 3

Human TRP-1 Has Tyrosine Hydroxylase but no DOPA Oxidase activity

Protein kinase C-b-mediated complex formation

(TRP-1)

1

2

3


Ex Vivo test - Protocol Skin explants (33 year old Caucasian woman) were treated with different treatments during 10 days: - Application of a cream containing 3% of Axolight every 2 days - Irradiation by UV every day. Number of TRP-1 positive melanocytes is measured by immunolabelling

Axolight efficiently inhibits melanogenesis via TRP-1

Inh

ibitio

n o

f m

ela

no

ge

ne

sis

via

TR

P-1

With Axolight positive TRP-1 melanocytes are reduced by 88%*

TRP-1 positive melanocytes

Composition of the cream with 3% of Axolight

Ingredients %

Xyliance 4

Caprylic/capric triglycerides 12

Aqua Qsp 100

Preservative Qs

Glycerin 1

Axolight 3


Ex Vivo test - Protocol Lightness of the skin (L*) is measured by chromameter Measure of melanine is done by image analysis

Axolight inhibits melanogenesis and prevents UV-induced coloration

Inh

ibitio

n o

f m

ela

no

ge

ne

sis

Inhibition of explant color

> Axolight maintains luminosity of the skin despite UV irradiation

Visualization of melanin at D10 a. Control batch b. Batch treated with 3% of Axolight

a b

> Axolight reduces melanin quantity by 18%*

Composition of the cream with 3% of Axolight

Ingredients %

Xyliance 4

Caprylic/capric triglycerides 12

Aqua Qsp 100

Preservatives Qs

Glycerin 1

Axolight 3


Me

lan

og

en

esi

s :

a d

ou

ble

eff

ec

t


In Vivo test - Protocol Efficacy of Axolight is evaluated on a panel of volunteers (22 Asian-type women, medium age of 37 years old) Application twice a day during 56 days, on the forearm, of 1 cream with 3% of Axolight or 1 cream with 2% of arbutin. The coloration of the skin is measured with a mexameter and a spectrocolorimeter (A mexameter mesures melanin quantity; the lower the mexametric index is, the lighter the skin is.)

Axolight works faster than arbutin

Lig

hte

nin

g e

ffe

ct

- In

Viv

o t

est

Variation of mexametric index (lightening effect)

91% of volunteers have shown a lightening effect (vs 82% for cream with arbutin)

Axolight presents significant results from 28 days.

Variation of luminosity L* vs D0


Biodegradability

ECOCERT

Ecocert approved

Axolight is environmentally friendly

En

viro

nm

en

t

Pourcentage de biodégradation par rapport à la DThO

Axolight is classified as readily biodegradable


Caracteristics

INCI Name: Water (and) Hydrolyzed wheat flour

Aspect : yellow to amber liquid

Odor: odorless

Preservative : none

Dosage : 2-3%

Cosmetic uses

Axolight is recommended in :

• lightening products

• Anti-aging products, for age spot prevention

• ECOCERT products

Co

sme

tic

use

s

APPLICATIONS BENEFITS EXEMPLES

Sun Protection

PREVENT

Sun screen UV Protection

Age spot prevention

care

Day cream Night cream Cleansing gel Foam Lotion Mask

Whitening care

LIGHTEN Complexion lightening

Tinted cream nude make-up

After-sun EXTEND Cream


• Patented and Ecocert validated

• Efficacy proved

• Double inhibition of melanogenesis

• Innovative mode of action

• Environment friendly

Put the light on your beauty!

Co

nc

lusi

on

axolight

Health & Medicine

export presentation

immunolabelling axolight

human trp

activation of tyrosinase

activated tyrosinase

ldopa substrate of tyrosinase

number of trp

complex formation trp